Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Medical School

Harvard Medical School

2008, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Pediatric Hematology-Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

2014, Boston, MA

Certifications

  • American Board of Pediatrics (General)
  • American Board of Pediatrics (Hematology-Oncology)

Professional History

Dr. Kamihara received her medical degree from Harvard Medical School and her PhD in genetics from MIT. She completed her pediatric residency training at Boston Children’s Hospital/Boston Medical Center and her fellowship in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital. She is currently an attending physician in the Jimmy Fund Clinic. Her research and clinical interests focus on pediatric cancer predisposition syndromes.

Dr. Kamihara serves as an expert for the Department of Hematology-Oncology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

Publications

  1. Wilms Tumor in Children with AMER1/WTX Germline Pathogenic Variants: A Multicenter Case Series. Pediatr Blood Cancer. 2025 May 21; e31798. View Abstract

  2. Update on Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2025 May 15; 31(10):1831-1840. View Abstract

  3. Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries. Cancer. 2025 May 01; 131(9):e35862. View Abstract

  4. Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children. Clin Cancer Res. 2025 May 01; 31(9):1573-1579. View Abstract

  5. Prevalence, Characteristics, and Management of Pancreatic Tumors Among Children With Tuberous Sclerosis Complex. J Pediatr Surg. 2025 Apr 24; 60(7):162339. View Abstract

  6. Prognostic Significance of Germline DICER1 Pathogenic or Likely Pathogenic Variants in Outcomes of Ovarian Sertoli-Leydig Cell Tumor. JCO Precis Oncol. 2025 Apr; 9:e2400902. View Abstract

  7. Update on Surveillance in Von Hippel-Lindau Disease. Clin Cancer Res. 2025 Apr 15. View Abstract

  8. Author Correction: Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency. Nat Commun. 2025 Mar 24; 16(1):2870. View Abstract

  9. Case Series of Patients With FGFR1-Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clin Endocrinol (Oxf). 2025 Jun; 102(6):626-634. View Abstract

  10. Pan-cancer multi-omic model of LINE-1 activity reveals locus heterogeneity of retrotransposition efficiency. Nat Commun. 2025 Feb 28; 16(1):2049. View Abstract

  11. Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex. Clin Cancer Res. 2025 Jan 17; 31(2):234-244. View Abstract

  12. DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clin Cancer Res. 2024 Dec 16; 30(24):5681-5692. View Abstract

  13. Managing CDH1 Cancer Risks in a Child: Complex Decision Making in a Family With Hereditary Diffuse Gastric Cancer. Am J Med Genet A. 2025 Feb; 197(2):e63897. View Abstract

  14. Strategies for Academic Advisors and Mentors to Support Medical Students Entering Clinical Rotations. Med Sci Educ. 2024 Dec; 34(6):1541-1550. View Abstract

  15. Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 01; 30(15):3137-3143. View Abstract

  16. Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors. Clin Cancer Res. 2024 Jun 03; 30(11):2342-2350. View Abstract

  17. Anaplastic sarcoma of the kidney (DICER1-sarcoma of the kidney): A report from the International Pleuropulmonary Blastoma/DICER1 Registry. Pediatr Blood Cancer. 2024 Aug; 71(8):e31090. View Abstract

  18. Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries. Gynecol Oncol. 2024 07; 186:117-125. View Abstract

  19. Biallelic EPCAM deletions induce tissue-specific DNA repair deficiency and cancer predisposition. NPJ Precis Oncol. 2024 Mar 11; 8(1):69. View Abstract

  20. Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors. Pediatr Blood Cancer. 2023 11; 70(11):e30643. View Abstract

  21. Rare Tumors: Opportunities and challenges from the Children's Oncology Group perspective. EJC Paediatr Oncol. 2023 Dec; 2. View Abstract

  22. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  23. Perspectives of Rare Disease Experts on Newborn Genome Sequencing. JAMA Netw Open. 2023 05 01; 6(5):e2312231. View Abstract

  24. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. Pediatr Blood Cancer. 2023 06; 70(6):e30262. View Abstract

  25. Type I and Ir pleuropulmonary blastoma (PPB): A report from the International PPB/DICER1 Registry. Cancer. 2023 02 15; 129(4):600-613. View Abstract

  26. Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward. J Clin Oncol. 2023 02 01; 41(4):727-731. View Abstract

  27. Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila). 2022 10 04; 15(10):645-652. View Abstract

  28. Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry. J Clin Oncol. 2023 02 01; 41(4):778-789. View Abstract

  29. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589. View Abstract

  30. Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. Am J Hum Genet. 2022 06 02; 109(6):1026-1037. View Abstract

  31. 68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. Pediatr Blood Cancer. 2022 08; 69(8):e29740. View Abstract

  32. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510. View Abstract

  33. Thyroid Nodules in Children With Familial Adenomatous Polyposis. Am J Gastroenterol. 2022 07 01; 117(7):1166-1168. View Abstract

  34. Germline pathogenic variants in cancer risk genes among patients with thyroid cancer and suspected predisposition. Cancer Med. 2022 04; 11(8):1745-1752. View Abstract

  35. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5. View Abstract

  36. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021 Dec 01; 7(12):1806-1814. View Abstract

  37. Belzutifan, a Potent HIF2a Inhibitor, in the Pacak-Zhuang Syndrome. N Engl J Med. 2021 11 25; 385(22):2059-2065. View Abstract

  38. Different Fumarate Hydratase Gene Variants Are Associated With Distinct Cancer Phenotypes. JCO Precis Oncol. 2021 11; 5:1568-1578. View Abstract

  39. Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. J Clin Oncol. 2021 09 01; 39(25):2779-2790. View Abstract

  40. Natural History of Thyroid Disease in Children with PTEN Hamartoma Tumor Syndrome. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1121-e1130. View Abstract

  41. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921. View Abstract

  42. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies-Response. Clin Cancer Res. 2019 03 01; 25(5):1689-1690. View Abstract

  43. It's ALL in the Family: IKZF1 and Hereditary Leukemia. Cancer Cell. 2018 05 14; 33(5):798-800. View Abstract

  44. DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clin Cancer Res. 2018 05 15; 24(10):2251-2261. View Abstract

  45. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract

  46. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 07 01; 23(13):e98-e106. View Abstract

  47. Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 07 01; 23(13):e123-e132. View Abstract

  48. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clin Cancer Res. 2017 Jun 15; 23(12):e62-e67. View Abstract

  49. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e68-e75. View Abstract

  50. PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e76-e82. View Abstract

  51. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). View Abstract

  52. Socioeconomic status and global variations in the incidence of neuroblastoma: call for support of population-based cancer registries in low-middle-income countries. Pediatr Blood Cancer. 2017 02; 64(2):321-323. View Abstract

  53. Parental hope for children with advanced cancer. Pediatrics. 2015 May; 135(5):868-74. View Abstract

  54. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View Abstract

  55. Neuromyelitis optica in an adolescent after bone marrow transplantation. Pediatr Neurol. 2015 Jan; 52(1):119-24. View Abstract

  56. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014 Jun; 35(6):654-62. View Abstract

  57. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001 Apr 10; 98(8):4605-10. View Abstract

  58. Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol. 2001 Mar 19; 152(6):1233-46. View Abstract
BESbswy